ADMA Biologics Q2 GAAP net income rises 11% to $37.8 million; revenue increases 2% to $124.4 million

• ADMA Biologics posted 2Q 2026 GAAP net income of USD 37.8 million, up 11% year-over-year; GAAP basic EPS rose 17% to USD 0.17.
• Revenue climbed 2% year-over-year to USD 124.4 million, driven by ASCENIV revenue of USD 102.9 million, up 24%.
• BIVIGAM revenue fell 49% year-over-year to USD 19.4 million, though utilization stabilized with sequential improvement in demand and revenue.
• Gross margin widened 14 percentage points to 69% on a mix shift toward ASCENIV and the yield-enhanced manufacturing process approved in 2025.
• Reiterated FY2026 guidance for revenue of USD 530 million to USD 560 million, adjusted EBITDA of USD 265 million to USD 300 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADMA Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608051605PRIMZONEFULLFEED9804346) on August 05, 2026, and is solely responsible for the information contained therein.